Lexaria Bioscience Corp.
LEXXNASDAQHealthcare● Active
$0.65
+$0.01(+1.51%)
Market Cap$13219377
P/E Ratio—
52W High$1.55
52W Low$0.46
Lexaria Bioscience Corp. (LEXX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LEXX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-08 | 2024-08 | 2023-08 | 2022-08 | 2021-08 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.71M | $0.46M | $0.23M | $0.26M | $0.72M |
| Cost of Revenue | $0.00M | $0.00M | $0.03M | $0.07M | $0.18M |
| Gross Profit | $0.70M | $0.46M | $0.19M | $0.18M | $0.55M |
| Gross Margin %(computed) | 99.61% | 98.96% | 86.07% | 71.87% | 75.74% |
| Operating Expenses | |||||
| R&D Expenses | $8.24M | $2.36M | $3.67M | $1.84M | $1.26M |
| G&A Expenses | $4.35M | $3.85M | $3.06M | $4.96M | $4.97M |
| Total Operating Expenses | $12.58M | $6.21M | $6.73M | $6.80M | $6.23M |
| Operating Income | ($11.88M) | ($5.75M) | ($6.53M) | ($6.62M) | ($5.69M) |
| Operating Margin %(computed) | — | — | — | — | -786.85% |
| Interest Income | $0.00M | $0.01M | $0.04M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($11.91M) | ($5.81M) | ($6.71M) | ($7.38M) | ($4.16M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($11.90M) | ($5.80M) | ($6.66M) | ($7.27M) | ($4.03M) |
| Net Margin %(computed) | — | — | — | — | -557.19% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.66 | $-0.47 | $-1.01 | $-1.24 | $-0.92 |
| Wtd Avg Shares | 18.00M | 12.38M | 6.61M | 5.89M | 4.39M |
| EBITDA | ($11.79M) | ($5.68M) | ($6.39M) | ($6.52M) | ($5.54M) |
| EBITDA Margin %(computed) | — | — | — | — | -766.43% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Lexaria Bioscience Corp. data
About Lexaria Bioscience Corp. (LEXX) Income Statement
Lexaria Bioscience Corp. (LEXX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LEXX reported revenue of $0.00B, gross profit of $0.00B (gross margin 99.61%), and net income of ($0.01B) — a net profit margin of -1686.00%.
Frequently asked questions
LEXX · 4 questionsLexaria Bioscience Corp. (LEXX) reported revenue of $0.00B for 2025, up 52.0% year-over-year.
LEXX revenueLEXX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09